Prasugrel Beats Ticagrelor and Clopidogrel After Heart Stenting
A 48,904-patient meta-analysis finds prasugrel reduces heart attacks and stent clots better than its rivals after PCI.
Summary
When cardiologists place a stent in a blocked coronary artery, patients must take a blood-thinning medication to prevent clotting. Three drugs compete for that role: clopidogrel, ticagrelor, and prasugrel. This large meta-analysis pooled 15 randomized trials involving nearly 49,000 patients to compare all three head-to-head. Prasugrel came out on top — cutting the risk of major cardiovascular events by 20% versus clopidogrel, driven by fewer heart attacks and a 52% reduction in stent thrombosis. Ticagrelor did not significantly reduce overall cardiovascular events versus clopidogrel and raised the risk of major bleeding, including a near-doubling of intracranial hemorrhage. Prasugrel also outperformed ticagrelor directly, with fewer heart attacks and stent clots. The authors conclude prasugrel offers the best balance of benefit and safety for PCI patients.
Detailed Summary
After a cardiologist places a coronary stent, patients face a critical choice of antiplatelet therapy to prevent the stent from clotting and to reduce future heart attacks. For years, clopidogrel was the standard, but newer agents — ticagrelor and prasugrel — were developed to provide stronger, more consistent platelet inhibition. Exactly how these drugs compare across a broad PCI population has remained uncertain, prompting this rigorous analysis.
Researchers conducted a systematic review and mixed-treatment-comparison meta-analysis of 15 randomized clinical trials published through November 2025, enrolling 48,904 patients (mean age 63.2 years; 27.3% female). The primary efficacy outcome was major adverse cardiovascular events (MACE), and the primary safety outcome was major bleeding. All three agents were compared simultaneously using network meta-analytic methods.
Prasugrel demonstrated a 20% reduction in MACE versus clopidogrel (OR 0.80), driven by a 29% lower rate of myocardial infarction and a striking 52% reduction in stent thrombosis. Against ticagrelor, prasugrel still showed significant advantages: 17% fewer MACE, 22% fewer myocardial infarctions, and 34% fewer stent thromboses. Ticagrelor failed to reduce overall MACE compared to clopidogrel, reduced stent thrombosis modestly, but increased major bleeding by 24% and nearly doubled intracranial hemorrhage risk.
For clinicians, these findings challenge the growing preference for ticagrelor in many guidelines and suggest prasugrel may be underutilized. The drug's superior platelet inhibition appears to translate meaningfully into fewer ischemic events without an excess bleeding burden in this pooled population.
Caveats include that the analysis is based on the abstract only, and full data on patient subgroups — such as those with prior stroke (a prasugrel contraindication), bleeding history, or body weight — are not available from the abstract. Individual trial heterogeneity in patient populations, stent types, and follow-up duration may also influence results.
Key Findings
- Prasugrel reduced major cardiovascular events by 20% and stent thrombosis by 52% versus clopidogrel after PCI.
- Ticagrelor did not significantly reduce overall MACE versus clopidogrel and raised major bleeding risk by 24%.
- Ticagrelor nearly doubled intracranial hemorrhage risk compared to clopidogrel (OR 1.89).
- Prasugrel outperformed ticagrelor directly, cutting MI risk by 22% and stent thrombosis by 34%.
- Prasugrel ranked first across all ischemic endpoints in network meta-analysis of 15 trials.
Methodology
This is a systematic review and mixed-treatment-comparison (network) meta-analysis of 15 randomized clinical trials identified via PubMed and Embase through November 2025. Random-effects odds ratios with 95% confidence intervals were calculated per PRISMA guidelines. The network approach allowed simultaneous indirect and direct comparisons of all three P2Y12 inhibitors.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; subgroup analyses and individual patient-level data are unavailable. Prasugrel carries a known contraindication in patients with prior stroke or TIA, and how trial populations handled this exclusion is unclear from the abstract. Heterogeneity across 15 trials in terms of patient profiles, stent generations, and follow-up duration may affect the generalizability of pooled estimates.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.